-transparent.png){kind=logo}
Twenty-three patients with advanced renal cell cancer were treated with Didemnin B. One partial response was achieved (5%) in 21 evaluable patients. An allergic reaction was noted in four patients including one patient with anaphylaxis. Didemnin B is not recommended in the treatment of renal cell carcinoma.
Related Publications
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
January 1994,
Investigational new drugs,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
January 2002,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
September 2004,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
August 2003,
Investigational new drugs,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
April 1996,
American journal of clinical oncology,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
August 1992,
Investigational new drugs,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
January 1994,
Investigational new drugs,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
May 2010,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
January 1985,
Cancer treatment reports,
R Motzer, and
H Scher, and
D Bajorin, and
C Sternberg, and
G J Bosl
January 2001,
Investigational new drugs,
